WaveMan
WaveMan · Company
GLUE · Monte Rosa Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

GLUE Monte Rosa Therapeutics (GLUE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001826457
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
109
13F, latest reported quarter
Conversions, 180 days
15
Codes C/M, not in net · $635.7K priced

What the filings say about GLUE

Insiders, 180 days
-$2.6M net sold
6 sellers · 0% of sales under a 10b5-1 plan

Monte Rosa Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Monte Rosa Therapeutics, Inc. insiders sold a net $2.6M of stock across 48 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Bowen Matthew
Principal Accounting Officer
SELL
2026-10-06 SECtraded 2026-10-05
13
$137
+3.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.1% of the 25,891 shares held after it.
  • No other insider sold within 30 days.
  • 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Bowen Matthew sold about $137 of GLUE on Oct 5, 2026; 109 funds added in the latest 13F quarter.
Warmuth Markus
President & CEO
SELL
2026-07-17 SECtraded 2026-07-16
9,500
$220.2K
-55.4%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Jun 1, 2026.
  • The trade is 1.6% of the 585,038 shares held after it.
  • 4 other insiders sold within 30 days.
  • 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Warmuth Markus sold about $220.2K of GLUE on Jul 16, 2026; 4 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.
Champoux Jennifer
Chief Operating Officer
SELL
2026-07-16 SECtraded 2026-07-15
4,351
$101.7K
-57.3%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 23, 2026.
  • The trade is 7.0% of the 62,371 shares held after it.
  • 4 other insiders sold within 30 days.
  • 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Champoux Jennifer sold about $101.7K of GLUE on Jul 15, 2026; 4 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.
Townson Sharon
Chief Scientific Officer
SELL
2026-07-07 SECtraded 2026-07-06
5,600
$130.2K
-56.4%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 23, 2026.
  • The trade is 8.2% of the 68,245 shares held after it.
  • 4 other insiders sold within 30 days.
  • 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Townson Sharon sold about $130.2K of GLUE on Jul 6, 2026; 4 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.
Townson Sharon
Chief Scientific Officer
SELL
2026-07-07 SECtraded 2026-07-06
400
$9.7K
-56.4%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 23, 2026.
  • The trade is 0.6% of the 67,845 shares held after it.
  • 4 other insiders sold within 30 days.
  • 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Townson Sharon sold about $9.7K of GLUE on Jul 6, 2026; 4 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.
48 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 43 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.6M over 180 days
-$137 over 90 days
below 72% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
109 funds bought in last quarter
more than 72% of Pharma & Biotech
Revenue
+63.5% year over year
more than 80% of Pharma & Biotech
Margin
-31.2% net margin
more than 54% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
36.1% of the float short (float per yahoo 2026-10-26) · 18.0 days to cover · settled 2026-09-30
more than 97% of Pharma & Biotech
What changed in the last 30 days
Oct 6Principal Accounting Officer Bowen Matthew sold $137 (Oct 5)

Watch GLUE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+1.0%12M
-6%+44%+94%+144%2025-102025-122026-022026-042026-062026-082026-10 2026-06-24 · Janku Filip sold $642.6K2026-02-27 · Dunn Edmund sold $455.5K2026-06-23 · Janku Filip sold $239.5K2026-06-29 · Manning Anthony M. sold $231.1K2026-07-16 · Warmuth Markus sold $220.2K2026-05-21 · Manning Anthony M. sold $180.1K2026-02-23 · Janku Filip sold $179.2K2026-01-05 · Warmuth Markus sold $153.7K2026-04-14 · Warmuth Markus sold $141.1K2026-06-29 · Janku Filip sold $137.7K2026-06-30 · Janku Filip sold $132.5K2026-07-06 · Townson Sharon sold $130.2K2026-05-29 · Townson Sharon sold $119.2K2026-05-01 · Warmuth Markus sold $103.4K2026-04-09 · Nickson Philip sold $103.4K2026-07-15 · Champoux Jennifer sold $101.7K2026-03-02 · Warmuth Markus sold $98.0K2026-06-01 · Warmuth Markus sold $97.0K2026-01-07 · Warmuth Markus sold $86.2K2026-06-23 · Townson Sharon sold $60.0K2026-06-17 · Townson Sharon sold $57.0K2026-01-05 · Nickson Philip sold $47.9K2026-01-05 · Janku Filip sold $47.9K2026-01-05 · Townson Sharon sold $47.9K2026-05-27 · Champoux Jennifer sold $43.5K2026-06-23 · Champoux Jennifer sold $43.5K2026-05-22 · Champoux Jennifer sold $41.3K2026-06-17 · Champoux Jennifer sold $41.3K2026-01-05 · Champoux Jennifer sold $39.9K2026-01-07 · Warmuth Markus sold $34.6K2026-01-05 · Dunn Edmund sold $15.8K2026-07-06 · Townson Sharon sold $9.7K2026-03-02 · Dunn Edmund sold $9.4K2026-06-01 · Warmuth Markus sold $9.2K2026-01-07 · Warmuth Markus sold $7.6K2026-03-04 · Dunn Edmund sold $2.5K2026-10-05 · Bowen Matthew sold $1372026-07-16 · MARKUS WARMUTH filed to sell $220.2K2026-07-15 · Champoux Jennifer filed to sell $101.7K2026-06-30 · FILIP JANKU filed to sell $129.2K2026-06-29 · FILIP JANKU filed to sell $133.7K2026-06-29 · ANTHONY M MANNING filed to sell $231.1K2026-06-24 · FILIP JANKU filed to sell $621.3K2026-06-23 · Champoux Jennifer filed to sell $40.0K2026-06-23 · EDMUND DUNN filed to sell $345.0K2026-06-23 · FILIP JANKU filed to sell $221.1K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GLUE: institutional holders (13F)

13F holdings, latest reported quarter
NEA Management Company, LLC
7,692,298 sh
$186.2M
BlackRock, Inc.
6,843,087 sh
$165.6M
TCG Crossover Management, LLC
4,622,151 sh
$111.9M
Vestal Point Capital, LP
4,600,000 sh
$111.3M
BVF INC/IL
4,460,886 sh
$108.0M

Congress trades in GLUE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GLUE planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
MARKUS WARMUTH
Filed 2026-07-16
$220.2K
Champoux Jennifer
Filed 2026-07-15
$101.7K
FILIP JANKU
Filed 2026-06-30
$129.2K
FILIP JANKU
Filed 2026-06-29
$133.7K
ANTHONY M MANNING
Filed 2026-06-29
$231.1K

GLUE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AlphaCentric Life Sciences and Healthcare Fund
$306.0K position · as of 2026-06-30
0.7%
Nomura Healthcare Fund
$4.8M position · as of 2026-06-30
0.6%
Virtus Biotech Clinical Trials Etf
$281.6K position · as of 2026-07-31
0.6%
Ultra-Small Company Market Fund
$726.0K position · as of 2026-06-30
0.5%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$51.2M position · as of 2026-06-30
0.5%
PROFUND VP BIOTECHNOLOGY
$226.8K position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
1 active
1
Phase 2
1 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $2.6M sold by insiders over 180 days, 109 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GLUE financials

Revenue growth
+63.5%
XBRL, annual
Net margin
-31.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$28.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-560.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$32.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-42.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-30.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-38.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
-3.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$123.7M$75.6M$0n/a
Operating income-$54.2M-$81.1M-$143.3M-$112.4M
Net income-$38.6M-$72.7M-$135.4M-$108.5M
Operating cash flow-$22.8M$42.0M-$43.8M-$92.5M
Cash$129.9M$224.3M$128.1M$54.9M
Dividends paid$0$0$0$0
SEC XBRL, fiscal years, as known on 2026-10-28

GLUE Stock Sonar score 5/7 axes

Find similar shapesCompare

GLUE ranks highest on growth (80th percentile) and institutional and government (72nd), and lowest on insider conviction (13th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
60
Inputs
  • Return on equity-42.7% · 59 pct, sector of 545
  • Return on assets-30.7% · 60 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-38.3% · 61 pct, sector of 576
Growth
80
Inputs
  • Revenue growth, YoY+63.5% · 80 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
13
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.6M · 25 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
72
Inputs
  • Funds adding, latest quarter109 · 72 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
46
Inputs
  • Short interest, % of float+36.1% · 2 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+3.5% · 90 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

GLUE filings, in plain words

Are Monte Rosa Therapeutics insiders buying or selling GLUE?

In the 180 days to 2026-10-28, Monte Rosa Therapeutics insiders were net sellers, a net $2.6M across purchases and sales reported on Form 4, by 6 sellers.

Read the full summary

In the 180 days to 2026-10-28, Monte Rosa Therapeutics insiders were net sellers of GLUE, a net $2.6M across purchases and sales reported on Form 4 by 6 sellers. None of the 21 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies